FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971390843> ?p ?o ?g. }

• W1971390843 endingPage "1375" @default.
• W1971390843 startingPage "1369" @default.
• W1971390843 abstract "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin. This drug has been proved active against several tumor systems, including some tumors resistant to doxorubicin, and also against human breast xenografts. It is also less cardiotoxic than doxorubicin. Mitoxantrone has been given to 335 patients in an i.v. perfusion of 12 mg/m2 or 14 mg/m2 every 3 weeks. Two hundred and sixty-three patients with advanced disease were evaluable for response: breast (94 patients), head and neck (40), kidney (20), bronchial (19), lymphomas (13) and various sites (77). Most of the patients had been previously treated with radiotherapy and chemotherapy, including/not including doxorubicin. In breast cancer three complete remissions (CR) and 16 partial remissions (PR) have been achieved (20%). The therapeutic activity was higher in patients who had not received any prior chemotherapy: 35 vs 15% (P = 0.06). The response rate observed at 14 mg/m2 (32%) was superior to the response rate observed at 12 mg/m2 (15%). However, no response has been reported in lung metastases (0/22). The median duration of response is 8 months. Mitoxantrone shows borderline activity in head and neck tumors (one CR and two PR out of 40 patients) but no activity in squamous cells of the lung (0/19). One CR and three PR have been seen out of 13 malignant lymphomas (four Hodgkin's disease and nine non-Hodgkin's lymphomas). The duration of response ranges from 10 to 24+ months. Myelosuppression was moderate and no severe leukopenia has been reported. Nausea and vomiting were seen in 50% of the patients. Four patients presented cardiac events associated with mitoxantrone, such as reversible congestive heart failure or a significant decrease in the ventricular ejection fraction. Alopecia was observed in 17 and 48% of the patients treated with 12 and 14 mg/m2 respectively. Due to its anti-tumoral activity, mainly in breast cancer, and its low hematological and cardiac toxicity, mitoxantrone must be considered as a major antimitotic." @default.
• W1971390843 created "2016-06-24" @default.
• W1971390843 creator A5000839359 @default.
• W1971390843 creator A5002404990 @default.
• W1971390843 creator A5016158055 @default.
• W1971390843 creator A5034364316 @default.
• W1971390843 creator A5035383163 @default.
• W1971390843 creator A5038734791 @default.
• W1971390843 creator A5045620374 @default.
• W1971390843 creator A5047164121 @default.
• W1971390843 creator A5047266225 @default.
• W1971390843 creator A5059471394 @default.
• W1971390843 creator A5067416808 @default.
• W1971390843 creator A5080259363 @default.
• W1971390843 creator A5083306545 @default.
• W1971390843 creator A5088824224 @default.
• W1971390843 date "1984-11-01" @default.
• W1971390843 modified "2023-10-18" @default.
• W1971390843 title "An EORTC phase II study of mitoxantrone in solid tumors and lymphomas" @default.
• W1971390843 cites W1968901213 @default.
• W1971390843 cites W1970901836 @default.
• W1971390843 cites W1989339760 @default.
• W1971390843 cites W2006520710 @default.
• W1971390843 cites W2042849799 @default.
• W1971390843 cites W2050502406 @default.
• W1971390843 cites W2051862853 @default.
• W1971390843 cites W2052357305 @default.
• W1971390843 cites W2228636347 @default.
• W1971390843 doi "https://doi.org/10.1016/0277-5379(84)90055-5" @default.
• W1971390843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6542006" @default.
• W1971390843 hasPublicationYear "1984" @default.
• W1971390843 type Work @default.
• W1971390843 sameAs 1971390843 @default.
• W1971390843 citedByCount "21" @default.
• W1971390843 crossrefType "journal-article" @default.
• W1971390843 hasAuthorship W1971390843A5000839359 @default.
• W1971390843 hasAuthorship W1971390843A5002404990 @default.
• W1971390843 hasAuthorship W1971390843A5016158055 @default.
• W1971390843 hasAuthorship W1971390843A5034364316 @default.
• W1971390843 hasAuthorship W1971390843A5035383163 @default.
• W1971390843 hasAuthorship W1971390843A5038734791 @default.
• W1971390843 hasAuthorship W1971390843A5045620374 @default.
• W1971390843 hasAuthorship W1971390843A5047164121 @default.
• W1971390843 hasAuthorship W1971390843A5047266225 @default.
• W1971390843 hasAuthorship W1971390843A5059471394 @default.
• W1971390843 hasAuthorship W1971390843A5067416808 @default.
• W1971390843 hasAuthorship W1971390843A5080259363 @default.
• W1971390843 hasAuthorship W1971390843A5083306545 @default.
• W1971390843 hasAuthorship W1971390843A5088824224 @default.
• W1971390843 hasConcept C121608353 @default.
• W1971390843 hasConcept C126322002 @default.
• W1971390843 hasConcept C143998085 @default.
• W1971390843 hasConcept C2776694085 @default.
• W1971390843 hasConcept C2778822529 @default.
• W1971390843 hasConcept C2780873365 @default.
• W1971390843 hasConcept C2780923524 @default.
• W1971390843 hasConcept C2781303535 @default.
• W1971390843 hasConcept C530470458 @default.
• W1971390843 hasConcept C71924100 @default.
• W1971390843 hasConcept C90924648 @default.
• W1971390843 hasConceptScore W1971390843C121608353 @default.
• W1971390843 hasConceptScore W1971390843C126322002 @default.
• W1971390843 hasConceptScore W1971390843C143998085 @default.
• W1971390843 hasConceptScore W1971390843C2776694085 @default.
• W1971390843 hasConceptScore W1971390843C2778822529 @default.
• W1971390843 hasConceptScore W1971390843C2780873365 @default.
• W1971390843 hasConceptScore W1971390843C2780923524 @default.
• W1971390843 hasConceptScore W1971390843C2781303535 @default.
• W1971390843 hasConceptScore W1971390843C530470458 @default.
• W1971390843 hasConceptScore W1971390843C71924100 @default.
• W1971390843 hasConceptScore W1971390843C90924648 @default.
• W1971390843 hasIssue "11" @default.
• W1971390843 hasLocation W19713908431 @default.
• W1971390843 hasLocation W19713908432 @default.
• W1971390843 hasOpenAccess W1971390843 @default.
• W1971390843 hasPrimaryLocation W19713908431 @default.
• W1971390843 hasRelatedWork W1970677298 @default.
• W1971390843 hasRelatedWork W2020274747 @default.
• W1971390843 hasRelatedWork W2067738925 @default.
• W1971390843 hasRelatedWork W2366392510 @default.
• W1971390843 hasRelatedWork W2367105124 @default.
• W1971390843 hasRelatedWork W2379009234 @default.
• W1971390843 hasRelatedWork W2388730008 @default.
• W1971390843 hasRelatedWork W2418970411 @default.
• W1971390843 hasRelatedWork W2559796776 @default.
• W1971390843 hasRelatedWork W4306163962 @default.
• W1971390843 hasVolume "20" @default.
• W1971390843 isParatext "false" @default.
• W1971390843 isRetracted "false" @default.
• W1971390843 magId "1971390843" @default.
• W1971390843 workType "article" @default.